Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -57K | -4M | -710K | -24K | -105K |
| EBITDA | -2K | 36M | -20M | 7M | -105K |
| Net Income | -2K | 16M | -20M | 7M | -397K |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Plandaí Biotechnology, Inc. (PLPL) is a Financial Services stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -100.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -100.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PLPL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLPL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PLPL Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PLPL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$397.0K
-105.8% YoY
Free Cash Flow
$0.0
+100.0% YoY
Revenue Growth
+0.0%
EPS Growth
-100.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -57K | -4M | -710K | -24K | -105K |
| EBITDA | -2K | 36M | -20M | 7M | -105K |
| Net Income | -2K | 16M | -20M | 7M | -397K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 100K | 0 | 0 | 7M | 7M |
| Total Liabilities | 155K | 443K | 2M | 9M | 26M |
| Shareholder Equity | -55K | -443K | -2M | -9M | -17M |
| Total Debt | 155K | 50K | 115K | 7M | 22M |
| Net Debt | 155K | 50K | 115K | 7M | 22M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
0
+100.0% YoY
Capital Expenditures
0
Free Cash Flow
0
+100.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
0.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.